January 27, 2020Circulation464 citationsOpen Access
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
View Full Paper
Structured PICO
Does dapagliflozin reduce the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus?
P
Population
High-risk patients with type 2 diabetes mellitus
I
Intervention
Dapagliflozin
O
Outcome
Incidence of reported episodes of AF/AFL adverse eventssafety
Dapagliflozin reduces the incidence of atrial fibrillation and atrial flutter adverse events in high-risk patients with type 2 diabetes mellitus.
Abstract
Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus. This effect was consistent regardless of the patient's previous history of AF, atherosclerotic cardiovascular disease, or HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01730534.